Abstract |
The efficacy of ME1036, a novel parenteral carbapenem, was compared with that of vancomycin by using a rabbit model of methicillin-resistant Staphylococcus aureus (MRSA) endocarditis. Compared with vancomycin, ME1036 reduced the bacterial counts in the vegetations at a lower dosage or over a shorter period of administration when it was used for the treatment of MRSA endocarditis.
|
Authors | Jun Nagura, Koji Kijima, Mizuyo Kurazono, Sho Takahata, Toshie Sugano, Yukari Tanaka, Yoko Hirai, Keiko Yamada, Yoshihiro Takayama, Eiki Shitara, Minoru Yonezawa |
Journal | Antimicrobial agents and chemotherapy
(Antimicrob Agents Chemother)
Vol. 49
Issue 8
Pg. 3526-8
(Aug 2005)
ISSN: 0066-4804 [Print] United States |
PMID | 16048975
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Carbapenems
- ME1036
- Vancomycin
|
Topics |
- Animals
- Anti-Bacterial Agents
(pharmacokinetics, therapeutic use)
- Carbapenems
(pharmacokinetics, therapeutic use)
- Colony Count, Microbial
- Disease Models, Animal
- Endocarditis, Bacterial
(drug therapy, microbiology)
- Female
- Humans
- Methicillin Resistance
- Microbial Sensitivity Tests
- Rabbits
- Staphylococcal Infections
(drug therapy, microbiology)
- Staphylococcus aureus
(drug effects, isolation & purification)
- Treatment Outcome
- Vancomycin
(pharmacokinetics, therapeutic use)
|